OliX Pharmaceuticals Inc.

Company Overview

OliX Pharmaceuticals Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics targeting various disorders using its proprietary RNAi technology. The company’s cp-asiRNA technology, a proprietary RNAi triggering structure, provides an efficient solution for delivering asiRNA intracellularly while minimizing adverse effects. Currently, OliX is focusing on developing locally administrable RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases, aiming for reduced costs and shorter development timelines. Additionally, the company has obtained GalNAc-asiRNA for targeting liver diseases.

OliX Pharmaceuticals initiated its ophthalmic program with the licensing and collaboration agreement for OLX301A in 2019. Subsequently, in 2020, the company expanded its agreement with Théa Open Innovation to include OLX301D, reaffirming its significant position in RNAi therapeutics.

Company's Business Segments

• Olix Technology : siRNA, asiRNA, cp-asiRNA, GalNAc-asiRNA.
• Olix Pipeline : OLX101A, OLX104C, OLX301A, OLX301D, OLX702A, OLX703A.